Kerry Group has announced the launch of a new rice-derived postbiotic ingredient, called Plenibiotic (Lactobacillus casei subsp. 327), that supports gut and skin health.
Kerry Group (Beloit, WI) has announced the launch of a new rice-derived postbiotic ingredient, called Plenibiotic (Lactobacillus casei subsp. 327), that supports gut and skin health. According to the company, the ingredient is backed by scientific research and has been shown to tolerant to a diverse range of temperatures, environment, is shelf stable, and requires a minimal serving size for efficacy. Plenibiotic can be formulated for both humans and pets.
“Plenibiotic is an exciting step forward in how we can leverage science to proactively address some of the greatest concerns facing consumers today,” said Jordan Dow, vice president, Kerry ProActive Health, in a press release. “Part of our mission in bringing innovative and sustainable new solutions to market requires us to radically rethink the role supplements can play in consumers’ lives by focusing on ingredients that enable a more proactive approach to health and wellness. Plenibiotic is a perfect example of how we’re propelling the industry forward with premium, clinically-supported ingredients to deliver leading-edge health and wellness solutions”
Plenibiotic is Kerry’s inaugural offering in the postbiotic space.
NPA’s lawsuit against FDA on NMN stayed pending agency’s decision on citizen petition
November 6th 2024The court has granted a joint motion for stay filed by NPA and FDA, pending the agency's decision on the citizen petition asking FDA to reverse its stance on NMN's status as a dietary ingredient.
Recent study compares the effectiveness of two probiotic products on colicky infants
October 31st 2024The study compared AB-Biotics and Kaneka Probiotics’ probiotic formulation of Bifidobacterium longum KABP®-042 and Pediococcus pentosaceus KABP®-041 to Lactobacillus reuteri DSM17938 (LR) from Biogaia.